3-amino-9-methoxy-2,6,8-trimethyl-10-phenyl-4,6-decadienoic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 3-amino-9-methoxy-2,6,8-trimethyl-10-phenyl-4,6-decadienoic acid
• 英文别名: 3-Amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid；(4E,6E)-3-amino-9-methoxy-2,6,8-trimethyl-10-phenyldeca-4,6-dienoic acid
• 化学式: C₂₀H₂₉NO₃
• 分子量: 331.455
• InChiKey: HJVCHYDYCYBBQX-CYZWUHAYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  72.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-amino-9-methoxy-2,6,8-trimethyl-10-phenyl-4,6-decadienoic acid 在 盐酸 作用下， 反应 21.0h， 生成 3-amino-2,6,8-trimethyl-10-phenyldeca-4E,6E-dienoic acid
  参考文献：
  名称：

  Formation of 3- amino-2, 6, 8-trimethyl-10-phenyldeca-4E 6E-dienoic acid from microcystin LR by the treatment with various proteases, and its detection in mouce liver

  摘要：

  Microcystin LR metabolism in mammals was examined. The degradation of microcystin LR by the enzymes, pepsin, trypsin and chymotrypsin, from porcine or human gastrointestinal tract was examined. Microcystin LR was digested by these proteases, but 3-amino-2, 6, 8-trimethyl-10-phenyldeca-4E, 6E-dienoic acid (DmADDA) was not formed from microcystin LR treated with pepsin and chymotrypsin. The formation of DmADDA was detected from microcystin LR treated with trypsin. Furthermore, DmADDA was detected from the male ddY mice liver orally administered microcystin LR. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0045-6535(97)10196-5

文献信息

• [EN] LIQUID COMPOSITIONS COMPRISING A LEVODOPA AMINO ACID CONJUGATE AND USES THEREOF<br/>[FR] COMPOSITIONS LIQUIDES COMPRENANT UN CONJUGUÉ D'ACIDES AMINÉS DE LÉVODOPA ET LEURS UTILISATIONS
  申请人：NEURODERM LTD

  公开号：WO2021044420A1

  公开（公告）日：2021-03-11

  Disclosed herein are liquid pharmaceutical formulations comprising levodopa amino acid conjugates that may further comprise a decarboxylase inhibitor, such as carbidopa, an antioxidant, a solvent, or any other pharmaceutically acceptable excipient. Further disclosed are methods of treating generative conditions and/or conditions characterized by reduced levels of dopamine in the brain, such as Parkinson's disease, comprising administering the disclosed liquid pharmaceutical formulations. Disclosed also are LDAA conjugate compounds.

  本文披露了包含左多巴氨基酸共轭物的液体药物配方，该共轭物可能进一步包含一个脱羧酶抑制剂，如卡比多巴，一种抗氧化剂，一种溶剂或任何其他药学上可接受的辅料。进一步披露了治疗神经退行性疾病和/或大脑中多巴胺水平降低的疾病的方法，例如帕金森病，包括给予披露的液体药物配方。还披露了LDAA共轭物化合物。
• Advanced drug development and manufacturing
  申请人：Los Alamos National Security, LLC

  公开号：EP2511844A2

  公开（公告）日：2012-10-17

  There is described an apparatus for measuring protein characteristics comprising an X-ray fluorescence (XRF) spectrometer comprising a source of polychromatic X-rays, an X-ray detector, a protein, a molecule that has been exposed to and at least weakly binds to the protein, a plurality of X-ray fluorescence signal data obtained by irradiating chemical elements in the protein and molecule with the polychromatic X-rays and a security system for maintaining records for the data from the plurality of X-ray fluorescence signal measurements. There is also described an x-ray microscope for measuring a sample.

  描述了一种测量蛋白质特性的仪器，该仪器包括一个 X 射线荧光 (XRF) 光谱仪，其中包括一个多色 X 射线源、一个 X 射线探测器、一个蛋白质、一个已暴露于该蛋白质并至少与该蛋白质弱结合的分子、通过用多色 X 射线照射蛋白质和分子中的化学元素而获得的多个 X 射线荧光信号数据，以及一个用于维护多个 X 射线荧光信号测量数据记录的安全系统。此外，还介绍了一种用于测量样品的 X 射线显微镜。
• Protocol for preconcentration and quantification of microcystins using LC-MS
  申请人：The University of Toledo

  公开号：US10436794B1

  公开（公告）日：2019-10-08

  Methods for detecting and quantifying one or more microcystin compounds in a sample are described. The methods may include a preconcentration step, and generally utilize an LC-MS or LC-MS/MS analysis with an Orbitrap Fusion mass spectrometer. The methods provide excellent recoveries and limits of quantification of microcystins.

  本文介绍了检测和量化样品中一种或多种微囊藻毒素化合物的方法。这些方法可能包括一个预浓缩步骤，通常使用 Orbitrap Fusion 质谱仪进行 LC-MS 或 LC-MS/MS 分析。这些方法可提供出色的微囊藻毒素回收率和定量限。
• Recombinant microcystin production
  申请人：NewSouth Innovations Pty Limited

  公开号：US11130784B2

  公开（公告）日：2021-09-28

  The present invention relates generally to methods for producing microcystin and recombinant cells capable of producing microcystin. The recombinant cells express exogenous microcystin synthase polypeptides under the control of an exogenous promoter, and further express an exogenous phosphopantethienyl transferase (PPTase). The present invention further relates to microcystin as produced in recombinant cells by the methods described herein.

  本发明一般涉及生产微囊藻毒素的方法和能够生产微囊藻毒素的重组细胞。重组细胞在外源启动子的控制下表达外源微囊藻毒素合成酶多肽，并进一步表达外源磷酸泛硫氨基转移酶（PPTase）。本发明还涉及用本文所述方法在重组细胞中产生的微囊藻毒素。
• Method for modifying microcystins and nodularins
  申请人：Cyano Biotech GmbH

  公开号：US11124818B2

  公开（公告）日：2021-09-21

  A method is used for producing a modified non-ribosomal peptide, e.g. a modified microcystin and/or modified nodularin (together CA), including the steps of: a) growing a modified non-ribosomal peptide producing cyanobacteria strain in a culture media, h) adding one or more modified substrates, preferably modified amino acids to said culture, and c) inoculating the non-ribosomal peptide, producing strain the presence of said modified substrates. The thus modified non-ribosomal peptide may be used for the therapy of various diseases.

  一种用于生产改性非核糖体肽的方法，例如改性微囊藻毒素和/或改性球藻毒素（合称 CA），包括以下步骤：a) 在培养基中培养产生改性非核糖体肽的蓝藻菌株；h) 向所述培养基中添加一种或多种改性底物，最好是改性氨基酸；以及 c) 接种非核糖体肽，产生存在所述改性底物的菌株。这样修饰的非核糖体肽可用于治疗各种疾病。